|
1
|
Appel S, Boehmler AM, Grünebach F, Müller
MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brümmendorf
TH and Brossart P: Imatinib mesylate affects the development and
function of dendritic cells generated from CD34+ peripheral blood
progenitor cells. Blood. 103:538–544. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Appel S, Rupf A, Weck MM, Schoor O,
Brümmendorf TH, Weinschenk T, Grünebach F and Brossart P: Effects
of imatinib on monocyte-derived dendritic cells are mediated by
inhibition of nuclear factor-kappaB and Akt signaling pathways.
Clin Cancer Res. 11:1928–1940. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Druker BJ and Lydon NB: Lessons learned
from the development of an abl tyrosine kinase inhibitor for
chronic myelogenous leukemia. J Clin Invest. 105:3–7. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Druker BJ, Talpaz M, Resta DJ, Peng B,
Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R,
Ohno-Jones S and Sawyers CL: Efficacy and safety of a specific
inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid
leukemia. N Engl J Med. 344:1031–1037. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Druker BJ, Sawyers CL, Kantarjian H, Resta
DJ, Reese SF, Ford JM, Capdeville R and Talpaz M: Activity of a
specific inhibitor of the BCR-ABL tyrosine kinase in the blast
crisis of chronic myeloid leukemia and acute lymphoblastic leukemia
with the Philadelphia chromosome. N Engl J Med. 344:1038–1042.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gambacorti-Passerini C, Antolini L, Mahon
FX, Guilhot F, Deininger M, Fava C, Nagler A, Della Casa CM, Morra
E, Abruzzese E, et al: Multicenter independent assessment of
outcomes in chronic myeloid leukemia patients treated with
imatinib. J Natl Cancer Inst. 103:553–561. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dietz AB, Souan L, Knutson GJ, Bulur PA,
Litzow MR and Vuk-Pavlovic S: Imatinib mesylate inhibits T cell
proliferation in vitro and delayed-type hypersensitivity in vivo.
Blood. 104:1094–1099. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen J, Schmitt A, Giannopoulos K, Chen B,
Rojewski M, Döhner H, Bunjes D and Schmitt M: Imatinib impairs the
proliferation and function of CD4+CD25+ regulatory T cells in a
dose-dependent manner. Int J Oncol. 31:1133–1159. 2007.PubMed/NCBI
|
|
9
|
Chen J, Schmitt A, Chen B, Rojewski M,
Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H,
Bunjes D and Schmitt M: Imatinib impairs CD8+ T lymphocytes
specifically directed against the leukemia-associated antigen
RHAMM/CD168 in vitro. Cancer Immunol Immunother. 56:849–861. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen Y, Peng C, Li D and Li S: Molecular
and cellular bases of chronic myeloid leukemia. Protein Cell.
1:124–132. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seggewiss R, Loré K, Greiner E, Magnusson
MK, Price DA, Douek DC, Dunbar CE and Wiestner A: Imatinib inhibits
T cell receptor-mediated T cell proliferation and activation in a
dose-dependent manner. Blood. 105:2473–2479. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mumprecht S, Matter M, Pavelic V and
Ochsenbein AF: Imatinib mesylate selectively impairs expansion of
memory cytotoxic T cells without affecting the control of primary
viral infections. Blood. 108:3406–3413. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leder C, Ortler S, Seggewiss R, Einsele H
and Wiendl H: Modulation of T effector function by imatinib at the
level of cytokine secretion. Exp Hematol. 35:1266–1271. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Catellani S, Pierri I, Gobbi M, Poggi A
and Zocchi MR: Imatinib treatment induces CD5+ B lymphocytes and
IgM natural antibodies with anti-leukemic reactivity in patients
with chronic myelogenous leukemia. PLoS One. 6:e189252011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vieira SA, Deininger MW, Sorour A,
Sinclair P, Foroni L, Goldman JM and Melo JV: Transcription factor
BACH2 is transcriptionally regulated by the BCR/ABL oncogene. Genes
Chromosomes Cancer. 32:353–363. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ono A, Kono K, Ikebe D, Muto A, Sun J,
Kobayashi M, Ueda K, Melo JV, Igarashi K and Tashiro S: Nuclear
positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
Genes Chromosomes Cancer. 46:67–74. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rosbrook GO, Stead MA, Carr SB and Wright
SC: The structure of the Bach2 POZ-domain dimer reveals an
intersubunit disulfide bond. Acta Crystallogr D Biol Crystallogr.
68:26–34. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oyake T, Itoh K, Motohashi H, Hayashi N,
Hoshino H, Nishizawa M, Yamamoto M and Igarashi K: Bach proteins
belong to a novel family of BTB basic leucine zipper transcription
factors that interact with MafK and regulate transcription through
the NF-E2 site. Mol Cell Biol. 16:6083–6095. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muto A, Hoshino H, Madisen L, Yanai N,
Obinata M, Karasuyama H, Hayashi N, Nakauchi H, Yamamoto M,
Groudine M and Igarashi K: Identification of Bach2 as a B
cell-specific partner for small maf proteins that negatively
regulate the immunoglobulin heavy chain gene 3′ enhancer. EMBO J.
17:5734–5743. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Igarashi K, Ochiai K and Muto A:
Architecture and dynamics of the transcription factor network that
regulates B to-plasma cell differentiation. J Biochem. 141:783–789.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kallies A and Nutt SL: Bach2: Plasma-cell
differentiation takes a break. EMBO J. 29:3896–3897. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nutt SL, Taubenheim N, Hasbold J, Corcoran
LM and Hodgkin PD: The genetic network controlling plasma cell
differentiation. Semin Immunol. 23:341–349. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dave SS: The polyphony of BACH2. Blood.
123:9502014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vardiman JW, Melo JV, Baccarani M and
Thiele J: Chronic myelogenous leukaemia, BCR-ABL1 positiveWHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H,
Thiele J and Vardiman JW: 4th. IARC; Lyon: pp. 32–37. 2008
|
|
25
|
Reddy EP and Aggarwal AK: The ins and outs
of bcr-abl inhibition. Genes Cancer. 3:447–454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jabbour E and Kantarjian H: Chronic
myeloid leukemia: 2012 update on diagnosis, monitoring and
management. Am J Hematol. 87:1038–1045. 2012. View Article : Google Scholar
|
|
27
|
Kreutzman A, Juvonen V, Kairisto V, Ekblom
M, Stenke L, Seggewiss R, Porkka K and Mustjoki S: Mono/oligoclonal
T and NK cells are common in chronic myeloid leukemia patients at
diagnosis and expand during dasatinib therapy. Blood. 116:772–782.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee SJ, Jung CW, Kim DY, Lee KH, Sohn SK,
Kwak JY, Kim HJ, Kim IH, Park S and Kim DH: Retrospective
multicenter study on the development of peripheral lymphocytosis
following second-line dasatinib therapy for chronic myeloid
leukemia. Am J Hematol. 86:346–3450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Riva G, Luppi M, Barozzi P, Quadrelli C,
Basso S, Vallerini D, Zanetti E, Morselli M, Forghieri F,
Maccaferri M, et al: Emergence of BCR-ABL-specific cytotoxic T
cells in the bone marrow of patients with Ph+ acute lymphoblastic
leukemia during long-term imatinib mesylate treatment. Blood.
115:1512–1518. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rohon P, Porkka K and Mustjoki S:
Immunoprofiling of patients with chronic myeloid leukemia at
diagnosis and during tyrosine kinase inhibitor therapy. Eur J
Haematol. 85:387–398. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoshida C, Yoshida F, Sears DE, Hart SM,
Ikebe D, Muto A, Basu S, Igarashi K and Melo JV: Bcr-Abl signaling
through the PI-3/S6 kinase pathway inhibits nuclear translocation
of the transcription factor Bach2, which represses the
antiapoptotic factor heme oxygenase-1. Blood. 109:1211–1219. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kamio T, Toki T, Kanezaki R, Sasaki S,
Tandai S, Terui K, Ikebe D, Igarashi K and Ito E: B cell-specific
transcription factor BACH2 modifies the cytotoxic effects of
anticancer drugs. Blood. 102:3317–3322. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen Z, Pittman EF, Romaguera J, Fayad L,
Wang M, Neelapu SS, McLaughlin P, Kwak L and McCarty N: Nuclear
translocation of B Cell-Specific transcription factor, BACH2,
modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
PLoS One. 8:e691262013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sakane-Ishikawa E, Nakatsuka S, Tomita Y,
Fujita S, Nakamichi I, Takakuwa T, Sugiyama H, Fukuhara S, Hino M,
Kanamaru A, et al: Prognostic significance of BACH2 expression in
diffuse large B cell lymphoma: A study of the osaka lymphoma study
group. J Clin Oncol. 23:8012–8017. 2005. View Article : Google Scholar : PubMed/NCBI
|
